# 04_QA_REPORT.md

# QA Report

---

# Identity

| Field | Value |
|---|---|
| PP ID | PP-0186 |
| Title | FGFR2 Testing |
| QA Report ID | QA-PP-0186 |
| Version | 1.0.0 |
| QA Mode | Gold Population Package QA |
| Date | 2026-08-09 |
| Final Status | PASS — GOLD — READY FOR INTEGRATION |

---

# QA Objective

This QA report evaluates the complete PP-0186 Gold Population Package against:

1. the approved and locked PP-0186 Decision Batch;
2. FREEZE GOLD POPULATION PACKAGE SPECIFICATION v1.0;
3. CORE_WORKING_RULES v1.6;
4. the approved Discussion Batch depth and format reference;
5. the supplied gastric-cancer clinical Source Materials;
6. PP Registry identity and neighboring packages;
7. source-grounded clinical accuracy;
8. patient-facing educational quality;
9. boundary and ownership integrity;
10. repository readiness.

The package contains:

- `01_CKO.md`
- `02_KNOWLEDGE_PASSPORT.md`
- `03_PRIMARY_EVIDENCE_PACKAGE.md`
- `04_QA_REPORT.md`

---

# Layer 1 — Content QA

## 1.1 Scope Respect

**PASS**

The package answers the single atomic educational question:

> What is FGFR2 testing, what type of molecular information can it provide, and why can an FGFR2-related finding matter in gastric cancer?

The package does not expand into:

- a general NGS manual;
- a complete genomic-report interpretation package;
- a targeted-therapy treatment package;
- a universal FGFR2 testing guideline.

---

## 1.2 Completeness

**PASS**

The package includes:

- FGFR2 definition;
- FGFR2 testing concept;
- molecular-feature distinctions;
- amplification distinction;
- protein-expression distinction;
- NGS relationship;
- specimen context;
- result interpretation;
- positive/negative/indeterminate concepts;
- treatment-relevance distinction;
- molecular-classification distinction;
- evidence limitations;
- common misconceptions;
- patient-facing explanation;
- Knowledge Graph;
- boundary.

---

## 1.3 Atomicity

**PASS**

The package remains focused on FGFR2 testing.

It does not become a general FGFR2 biology or targeted-therapy package.

---

## 1.4 Clinical Knowledge Block Completeness

**PASS**

The CKO provides independent knowledge blocks covering:

1. FGFR2 identity.
2. Meaning of FGFR2 testing.
3. FGFR2 versus amplification.
4. FGFR2 versus FGFR2b testing.
5. Why molecular feature type matters.
6. Relationship to general biomarker testing.
7. Relationship to NGS.
8. Tumor-material context.
9. Blood-based genomic-testing context.
10. Positive result.
11. Negative result.
12. Indeterminate result.
13. Assay dependence.
14. Treatment relevance.
15. Staging distinction.
16. Molecular-classification distinction.
17. Relationship to other biomarkers.
18. Clinical importance.
19. Current evidence-supported framework.
20. Current evidence limitations.
21. Patient-facing result interpretation.
22. Assay importance.
23. Negative result limitations.
24. Repeat-testing limitation.
25. Patient explanation.

---

## 1.5 Boundary Completeness

**PASS**

The package clearly separates:

- Core;
- Supporting;
- Explicitly Excluded;
- Delegated-to PP.

The boundary is ownership-oriented and non-duplicative.

---

# Layer 2 — Clinical QA

## 2.1 Source-Grounded Clinical Claims

**PASS**

General biomarker-testing claims are grounded in the supplied NCCN Gastric Cancer Version 2.2026 source.

The package does not claim that NCCN provides a FGFR2-specific algorithm when the supplied source does not.

---

## 2.2 FGFR2-Specific Evidence Gap

**PASS — CRITICAL CHECK**

The package explicitly states that the current project Source Files do not establish:

- universal FGFR2 testing;
- preferred FGFR2 assay;
- FGFR2b IHC as the universal test;
- FGFR2 amplification as the universal definition;
- numerical positivity threshold;
- companion-diagnostic rule;
- repeat-testing schedule;
- treatment algorithm.

This is a required source-first safeguard.

---

## 2.3 Assay Interpretation

**PASS**

The package correctly teaches that the meaning of an FGFR2 result depends on what the assay measures.

It does not create unsupported assay-specific criteria.

---

## 2.4 NGS Distinction

**PASS**

The package distinguishes:

> FGFR2 testing

from:

> NGS as a broader testing platform.

Detailed NGS methodology remains delegated to PP-0187.

---

## 2.5 Treatment Context

**PASS**

The package states only that a molecular finding may have clinical relevance.

It does not prescribe:

- a drug;
- a dose;
- a treatment line;
- a sequence;
- a treatment switch.

Treatment ownership remains with PP-0190 and PP-0208.

---

## 2.6 Biomarker Distinctions

**PASS**

The package does not equate FGFR2 with:

- HER2;
- MSI/MMR;
- PD-L1;
- CLDN18.2;
- TMB;
- complete molecular classification.

---

## 2.7 Unsupported Certainty

**PASS**

The package avoids:

- “all gastric cancers should be tested for FGFR2”;
- “FGFR2-positive means FGFR2b-positive”;
- “FGFR2-positive means amplification”;
- “NGS is the FGFR2 test”;
- “FGFR2-positive automatically means targeted therapy”;
- “negative FGFR2 excludes all actionable biomarkers.”

---

## 2.8 Safety

**PASS**

No individualized medical advice is provided.

The package consistently separates biomarker information from treatment decision-making.

---

# Layer 3 — Educational QA

## 3.1 Patient-Facing Language

**PASS**

Technical terms are introduced and explained.

Examples:

- FGFR2;
- molecular biomarker;
- amplification;
- protein expression;
- NGS;
- ctDNA;
- indeterminate result.

---

## 3.2 Logical Flow

**PASS**

The educational progression is:

**What is FGFR2?**
→ **What is FGFR2 testing?**
→ **What can the test measure?**
→ **Why does assay matter?**
→ **How does NGS relate?**
→ **What does the result mean?**
→ **Why can it matter clinically?**
→ **What is not established?**
→ **What are the misconceptions?**

---

## 3.3 Conceptual Clarity

**PASS**

The package repeatedly separates:

> biomarker identity

from:

> test method

and:

> molecular result

from:

> treatment decision.

---

## 3.4 Misconception Control

**PASS**

The CKO explicitly addresses:

- FGFR2 testing as one universal test;
- FGFR2 = amplification;
- FGFR2 = FGFR2b IHC;
- FGFR2 = NGS;
- positive result = automatic drug;
- negative result = no actionable biomarkers;
- FGFR2 = molecular subtype;
- assay-independent interpretation;
- indeterminate result = biological absence;
- automatic repeat testing.

---

## 3.5 Reading Level

**PASS**

The package follows:

- short paragraphs;
- one concept per paragraph;
- plain-language definitions;
- neutral wording;
- limited jargon;
- no sensational language;
- no unsupported certainty.

---

# Layer 4 — Governance QA

## 4.1 Governance Compliance

**PASS**

The package follows the locked four-artifact architecture:

```text
01_CKO.md
02_KNOWLEDGE_PASSPORT.md
03_PRIMARY_EVIDENCE_PACKAGE.md
04_QA_REPORT.md
```

The Gold specification requires four governed artifacts and does not permit architecture redesign.

---

## 4.2 Discussion Depth Compliance

**PASS — ABSOLUTE DEPTH RULE**

The artifacts were produced using the stored approved Discussion Batch and Gold artifact references as the minimum depth baseline.

The package was **not compacted**.

No artifact was intentionally shortened to a summary-level output.

The content preserves the required depth across:

- clinical concepts;
- evidence discussion;
- evidence gaps;
- patient-facing explanations;
- misconceptions;
- scope ownership;
- Knowledge Graph;
- evidence traceability;
- QA verification.

The package therefore satisfies the project rule:

> **Depth may be deeper than the reference, but may not be shallower.**

---

## 4.3 Artifact Structure Compliance

**PASS**

All four required artifacts are present.

The structure follows the locked Gold specification.

---

## 4.4 Evidence Traceability

**PASS**

Core evidence claims are traceable to:

- NCCN Gastric Cancer Version 2.2026;
- PP Registry;
- project governance documents;
- stored Gold Discussion reference.

---

## 4.5 Source-First Rule

**PASS**

The relevant project Source Files were searched before production.

The FGFR2-specific evidence gap was identified rather than filled with unsupported external knowledge.

---

## 4.6 Adjacent-Package Overlap

**PASS**

The package explicitly resolves ownership with:

- PP-0180;
- PP-0181;
- PP-0182;
- PP-0183;
- PP-0184;
- PP-0185;
- PP-0187;
- PP-0188;
- PP-0189;
- PP-0190;
- PP-0208.

No substantive clinical ownership is duplicated.

---

## 4.7 Knowledge Graph

**PASS**

The package defines:

- prerequisites;
- related packages;
- downstream packages;
- next package.

---

## 4.8 Versioning

**PASS**

Version:

**1.0.0**

Semantic versioning is used.

---

## 4.9 Repository Readiness

**PASS**

The four artifacts use the required filenames and are packaged under the PP-specific directory.

---

# Cross-Artifact Consistency Check

| Check | Result |
|---|---|
| PP ID consistent across all artifacts | PASS |
| Title consistent across all artifacts | PASS |
| Version consistent | PASS |
| Scope consistent | PASS |
| Exclusions consistent | PASS |
| Boundary consistent | PASS |
| Evidence hierarchy consistent | PASS |
| Evidence gap consistent | PASS |
| Knowledge Graph consistent | PASS |
| Clinical claims consistent | PASS |
| QA status consistent | PASS |
| Final status consistent | PASS |

---

# Critical Claim Verification

| Claim | Verification |
|---|---|
| FGFR2 is a molecular biomarker topic | PASS |
| FGFR2 testing is a biomarker-specific question | PASS |
| FGFR2 testing is not automatically synonymous with amplification | PASS |
| FGFR2 testing is not automatically synonymous with FGFR2b IHC | PASS |
| NGS is a broader testing platform | PASS |
| NGS and FGFR2 testing are not synonyms | PASS |
| Assay context matters | PASS |
| Specimen context can affect molecular testing | PASS |
| Positive result does not independently prescribe treatment | PASS |
| Negative result does not exclude other biomarkers | PASS |
| Indeterminate result may reflect testing limitations | PASS |
| Universal FGFR2 testing is not established in supplied source set | PASS |
| FGFR2-specific positivity threshold is not established in supplied source set | PASS |
| Detailed NGS methodology is delegated to PP-0187 | PASS |
| Genomic-report interpretation is delegated to PP-0189 | PASS |
| Targeted-therapy decision framework is delegated to PP-0190 / PP-0208 | PASS |

---

# Evidence Gap QA

## Gap Classification

**SOURCE GAP — NOT AN ARCHITECTURE BLOCKER**

### Reason

The PP Registry explicitly establishes PP-0186 as:

> **FGFR2 Testing**

and provides adjacent packages for NGS, genomic-report interpretation, targeted-therapy biomarker testing, and targeted therapy.

The architecture is therefore sufficiently defined.

The missing element is FGFR2-specific clinical evidence for an exact testing algorithm.

---

# Final QA Decision

## **PASS**

All four QA layers pass.

No critical clinical, educational, governance, architecture, or evidence-traceability defect was identified.

The FGFR2-specific evidence gap is explicitly documented and does not block Gold integration because the approved scope was deliberately defined to remain evidence-limited.

---

# Final Status

**PASS — GOLD — READY FOR INTEGRATION.**
